NCT02336451 (Ascend-7) is a Phase 2 clinical trial of Ceritinib in ALK-positive Non-small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT02336451?

NCT02336451 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02336451?

Interventions in NCT02336451: Ceritinib.

What condition does NCT02336451 study?

NCT02336451 studies ALK-positive Non-small Cell Lung Cancer.

Is NCT02336451 still recruiting?

NCT02336451 is currently completed. Last updated 21 April 2020.

Are results published for NCT02336451?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-04-21 · How we verify

NCT02336451: Ascend-7

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Completed Phase 2 Results posted Last updated 21 April 2020

What this trial tests

Phase 2 trial testing Ceritinib in ALK-positive Non-small Cell Lung Cancer in 156 participants. Completed in 6 February 2019.

Timeline

1 April 2015

Primary endpoint
6 February 2019

6 February 2019

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	156
Start date	1 April 2015
Primary completion	6 February 2019
Estimated completion	6 February 2019
Sites	57 locations across France, Hong Kong, Italy, Netherlands, Russia, Belgium, Taiwan, United Kingdom

Drugs / interventions tested

Ceritinib (ceritinib) — full drug profile →

Conditions studied

ALK-positive Non-small Cell Lung Cancer — all drugs for ALK-positive Non-small Cell Lung Cancer →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with ALK-positive Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Overall Response Rate (ORR) Per Investigator Assessment Primary · 43 months

Overall response rate (ORR) is defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) in the whole body as assessed per RECIST 1.1 by the investigator. CR: Disappearance of all non-nodal target and non-target lesions. In addition, all lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), and no new lesion is identified. PR: When all target lesions have disappeared or there is a decrease by at least 30% in the sum of diameter of all target lesions (taking as refer

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	35.7	21.6 – 52.0
Arm 2 (PrALKi=Y, PrBRad=N)	30.0	16.6 – 46.5
Arm 3 (PrALKi=N, PrBRad=Y)	50.0	21.1 – 78.9
Arm 4 (PrALKi=N, PrBRad=N)	59.1	43.2 – 73.7
Arm 5 (LepDis)	16.7	3.6 – 41.4

Disease Control Rate (DCR) Per Investigator Assessment Secondary · 43 months

DCR: percentage of parts. with best overall response of CR, PR or stable disease (SD) in the whole body, as assessed per RECIST 1.1 by investigator. CR: Disappearance of all non-nodal target and non-target lesions. In addition, all lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), \& no new lesion is identified. PR: When all target lesions have disappeared or there is a decrease by at least 30% in the sum of diameter of all target lesions (taking as reference the baseline sum of diameters) is observed and non-target lesions are not in

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	66.7	50.5 – 80.4
Arm 2 (PrALKi=Y, PrBRad=N)	82.5	67.2 – 92.7
Arm 3 (PrALKi=N, PrBRad=Y)	66.7	34.9 – 90.1
Arm 4 (PrALKi=N, PrBRad=N)	70.5	54.8 – 83.2
Arm 5 (LepDis)	66.7	41.0 – 86.7

Overall Intracranial Response Rate (OIRR) Per Modified RECIST 1.1 Per Investigator Assessment Secondary · 43 months

OIRR was calculated based on response assessments in the brain for patients having measurable brain metastases at baseline. OIRR was defined as the percentage of participants with a best overall confirmed response of CR or PR in the brain as assessed per modified RECIST 1.1. This was applied to the brain only. CR: Disappearance of all non-nodal target \& non-target lesions. All lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), \& no new lesion is identified. PR: When all target lesions have disappeared or decreased by at least 30% in

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	39.3	21.5 – 59.4
Arm 2 (PrALKi=Y, PrBRad=N)	27.6	12.7 – 47.2
Arm 3 (PrALKi=N, PrBRad=Y)	28.6	3.7 – 71.0
Arm 4 (PrALKi=N, PrBRad=N)	51.5	33.5 – 69.2
Arm 5 (LepDis)	12.5	0.3 – 52.7

Overall Intracranial Response Rate (OIRR) Per Modified RECIST 1.1 Per Blinded Independent Review Committee (BIRC) Assessment Secondary · 43 months

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	33.3	17.3 – 52.8
Arm 2 (PrALKi=Y, PrBRad=N)	24.1	10.3 – 43.5
Arm 3 (PrALKi=N, PrBRad=Y)	33.3	4.3 – 77.7
Arm 4 (PrALKi=N, PrBRad=N)	58.8	40.7 – 75.4
Arm 5 (LepDis)	20.0	2.5 – 55.6

Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per Investigator Assessment at Weeks 8 & 16 Secondary · Week 8 and Week 16

IDCR overall: percentage of participants with a best overall response of CR, PR, SD or non-CR/non-PD in the brain, as assessed per modified RECIST 1.1 by the Investigator. This was applied to the brain only. CR: Disappearance of all non-nodal target \& non-target lesions. All lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), \& no new lesion is identified. PR: When all target lesions have disappeared or there is a decrease by at least 30% in the sum of diameter of all target lesions (taking as reference the baseline sum of diameters)

IDCR at Week 8

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	71.4	55.4 – 84.3
Arm 2 (PrALKi=Y, PrBRad=N)	75.0	58.8 – 87.3
Arm 3 (PrALKi=N, PrBRad=Y)	58.3	27.7 – 84.8
Arm 4 (PrALKi=N, PrBRad=N)	68.2	52.4 – 81.4
Arm 5 (LepDis)	66.7	41.0 – 86.7

IDCR at Week 16

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	59.5	43.3 – 74.4
Arm 2 (PrALKi=Y, PrBRad=N)	62.5	45.8 – 77.3
Arm 3 (PrALKi=N, PrBRad=Y)	58.3	27.7 – 84.8
Arm 4 (PrALKi=N, PrBRad=N)	65.9	50.1 – 79.5
Arm 5 (LepDis)	50.0	26.0 – 74.0

Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per Investigator Assessment - Overall Secondary · 43 months

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	71.4	55.4 – 84.3
Arm 2 (PrALKi=Y, PrBRad=N)	85.0	70.2 – 94.3
Arm 3 (PrALKi=N, PrBRad=Y)	75.0	42.8 – 94.5
Arm 4 (PrALKi=N, PrBRad=N)	75.0	59.7 – 86.8
Arm 5 (LepDis)	66.7	41.0 – 86.7

Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per BIRC Assessment at Weeks 8 & 16 Secondary · Week 8 and Week 16

IDCR overall: percentage of participants with a best overall response of CR, PR, SD or non-CR/non-PD in the brain, as assessed per modified RECIST 1.1 by Investigator. This was applied to the brain only. CR: Disappearance of all non-nodal target \& non-target lesions. All lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), \& no new lesion is identified. PR: When all target lesions have disappeared or there is a decrease by at least 30% in the sum of diameter of all target lesions (taking as reference the baseline sum of diameters) is o

IDCR at 8 weeks

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	76.2	60.5 – 87.9
Arm 2 (PrALKi=Y, PrBRad=N)	80.0	64.4 – 90.9
Arm 3 (PrALKi=N, PrBRad=Y)	58.3	27.7 – 84.8
Arm 4 (PrALKi=N, PrBRad=N)	68.2	52.4 – 81.4
Arm 5 (LepDis)	66.7	41.0 – 86.7

IDCR at 16 weeks

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	69.0	52.9 – 82.4
Arm 2 (PrALKi=Y, PrBRad=N)	62.5	45.8 – 77.3
Arm 3 (PrALKi=N, PrBRad=Y)	58.3	27.7 – 84.8
Arm 4 (PrALKi=N, PrBRad=N)	68.2	52.4 – 81.4
Arm 5 (LepDis)	38.9	17.3 – 64.3

Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per BIRC Assessment - Overall Secondary · 43 months

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	73.8	58.0 – 86.1
Arm 2 (PrALKi=Y, PrBRad=N)	85.0	70.2 – 94.3
Arm 3 (PrALKi=N, PrBRad=Y)	66.7	34.9 – 90.1
Arm 4 (PrALKi=N, PrBRad=N)	75.0	59.7 – 86.8
Arm 5 (LepDis)	66.7	41.0 – 86.7

Time to Intracranial Tumor Response (TTIR) Per Modified RECIST 1.1 Per Investigator Assessment Secondary · 43 months

TTIR was defined as the time from the date of the first dose of ceritinib to the date of the first documented response (CR or PR) in the brain as assessed per modified RECIST 1.1 criteria for patients with measurable brain metastases at baseline. This was applied to the brain only. CR: Disappearance of all non-nodal target and non-target lesions. In addition, all lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), and no new lesion is identified. PR: When all target lesions have disappeared or there is a decrease by at least 30% in the

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	1.87	1.7 – 7.5
Arm 2 (PrALKi=Y, PrBRad=N)	1.84	1.6 – 9.1
Arm 3 (PrALKi=N, PrBRad=Y)	3.56	1.8 – 5.3
Arm 4 (PrALKi=N, PrBRad=N)	1.77	1.3 – 7.4
Arm 5 (LepDis)	1.80	1.8 – 1.8

Time to Intracranial Tumor Response (TTIR) Per Modified RECIST 1.1 Per BIRC Assessment Secondary · 43 months

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	1.91	1.7 – 5.6
Arm 2 (PrALKi=Y, PrBRad=N)	1.68	1.6 – 7.2
Arm 3 (PrALKi=N, PrBRad=Y)	6.31	3.5 – 9.1
Arm 4 (PrALKi=N, PrBRad=N)	1.81	1.3 – 9.2
Arm 5 (LepDis)	1.22	0.7 – 1.8

Duration of Intracranial Response (DOIR) by Modified RECIST 1.1 Per Investigator Assessment Secondary · 43 months

Defined as the time from the first documented response (PR or CR) in the brain to the date of the first documented disease progression in the brain or death due to any cause, amongst participants with measurable brain metastases at baseline and a confirmed response (PR or CR) in the brain as per modified RECIST 1.1. This was applied to the brain only. CR: Disappearance of all non-nodal target and non-target lesions. In addition, all lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), and no new lesion is identified. PR: When all target

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	9.2	3.7 – NA
Arm 2 (PrALKi=Y, PrBRad=N)	10.1	3.8 – 17.3
Arm 3 (PrALKi=N, PrBRad=Y)	NA	NA – NA
Arm 4 (PrALKi=N, PrBRad=N)	7.5	5.6 – 11.2
Arm 5 (LepDis)	5.5	NA – NA

Duration of Intracranial Response (DOIR) by Modified RECIST 1.1 Per BIRC Assessment Secondary · 43 months

Defined as the time from the first documented response (PR or CR) in the brain to the date of the first documented disease progression in the brain or death due to any cause, amongst participants with measurable brain metastases at baseline and a confirmed response (PR or CR) in the brain as per modified RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, all lymph nodes assigned a target or a non-target lesions must be non-pathological in size (\< 10 mm short axis), and no new lesion is identified. PR: When all target lesions have disappeared or there is

Group	Value	95% CI
Arm 1 (PrALKi=Y, PrBRad=Y)	11.0	3.8 – NA
Arm 2 (PrALKi=Y, PrBRad=N)	4.6	3.5 – 20.3
Arm 3 (PrALKi=N, PrBRad=Y)	NA	18.4 – NA
Arm 4 (PrALKi=N, PrBRad=N)	9.2	5.7 – 11.3
Arm 5 (LepDis)	3.4	2.0 – 4.7

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approx. 168 weeks.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm 1 (PrALKi=Y, PrBRad=Y)

Serious: 28/42 (67%)

Deaths: 8/42

Arm 2 (PrALKi=Y, PrBRad=N)

Serious: 17/40 (43%)

Deaths: 5/40

Arm 3 (PrALKi=N, PrBRad=Y)

Serious: 4/12 (33%)

Deaths: 3/12

Arm 4 (PrALKi=N, PrBRad=N)

Serious: 15/44 (34%)

Deaths: 6/44

Arm 5 (LepDis)

Serious: 11/18 (61%)

Deaths: 9/18

All Participants

Serious: 75/156 (48%)

Deaths: 31/156

Serious adverse events (81 terms)

Reaction	System	Arm 1 (PrALKi=Y, PrBRad=Y)	Arm 2 (PrALKi=Y, PrBRad=N)	Arm 3 (PrALKi=N, PrBRad=Y)	Arm 4 (PrALKi=N, PrBRad=N)	Arm 5 (LepDis)	All Participants
Pneumonia	Infections and infestations	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Seizure	Nervous system disorders	—	—	—	—	—	—
Pericarditis	Cardiac disorders	—	—	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Epilepsy	Nervous system disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—
Disease progression	General disorders	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—
Sudden death	General disorders	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Aphasia	Nervous system disorders	—	—	—	—	—	—
Dysarthria	Nervous system disorders	—	—	—	—	—	—
Confusional state	Psychiatric disorders	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Lymphadenopathy	Blood and lymphatic system disorders	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—
Left ventricular dysfunction	Cardiac disorders	—	—	—	—	—	—
Keratitis	Eye disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—

Other adverse events (132 terms — click to expand)

Reaction	System	Arm 1 (PrALKi=Y, PrBRad=Y)	Arm 2 (PrALKi=Y, PrBRad=N)	Arm 3 (PrALKi=N, PrBRad=Y)	Arm 4 (PrALKi=N, PrBRad=N)	Arm 5 (LepDis)	All Participants
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Seizure	Nervous system disorders	—	—	—	—	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Productive cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—

Most-reported serious reactions: Pneumonia, Hyperglycaemia, Seizure, Pericarditis, Pericardial effusion, Pyrexia, Epilepsy, Dyspnoea.

Data from ClinicalTrials.gov NCT02336451 adverse events section.

Sponsor's own description

This was a phase II, multi-center, open-label, five-arm study in which the efficacy and safety of oral ceritinib treatment was assessed in patients with NSCLC metastatic to the brain and/or to leptomeninges harboring a confirmed ALK rearrangement, using the FDA approved Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity criteria). If documentation of ALK rearrangement as described above was not locally available, a test to confirm ALK rearrangement was performed by a Novartis designated central laboratory. Patients waited for the central laboratory result of the ALK rearrangement status before initiating treatment with ceritinib.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW, Mehra R, Tan DSW, Felip E, et al · · 2016 · cited 355× · PMID 26973324 · DOI 10.1016/s1470-2045(15)00614-2
Pediatric low-grade glioma in the era of molecular diagnostics.
Ryall S, Tabori U, Hawkins C. · · 2020 · cited 254× · PMID 32164789 · DOI 10.1186/s40478-020-00902-z
Leptomeningeal metastasis from systemic cancer: Review and update on management.
Wang N, Bertalan MS, Brastianos PK. · · 2018 · cited 167× · PMID 29165794 · DOI 10.1002/cncr.30911
Clinical development of targeted and immune based anti-cancer therapies.
Seebacher NA, Stacy AE, Porter GM, Merlot AM. · · 2019 · cited 147× · PMID 30975211 · DOI 10.1186/s13046-019-1094-2
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
Chamberlain MC, Baik CS, Gadi VK, Bhatia S, et al · · 2017 · cited 134× · PMID 28031389 · DOI 10.1093/neuonc/now197
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I, Planchard D. · · 2016 · cited 89× · PMID 26753004 · DOI 10.1177/1758834015617355
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.
Remon J, Besse B. · · 2018 · cited 58× · PMID 29696132 · DOI 10.3389/fonc.2018.00088
Targeted therapy of brain metastases: latest evidence and clinical implications.
Di Lorenzo R, Ahluwalia MS. · · 2017 · cited 50× · PMID 29449898 · DOI 10.1177/1758834017736252

Verify or expand the search:

Other trials of Ceritinib

Trials testing the same drug.

NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
NCT03784014 — Molecular Profiling of Advanced Soft-tissue Sarcomas · Phase 3 · active not recruiting
NCT03737994 — Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cance · Phase 2 · active not recruiting
NCT03546894 — A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastati · completed
NCT03501368 — Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma · Phase 1 · completed

Other recruiting trials for ALK-positive Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07491497 — A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC · Phase 1, PHASE2 · recruiting
NCT06361589 — Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients · recruiting
NCT04900935 — Patient-centered, Optimal Integration of Survivorship and Palliative Care · NA · recruiting
NCT06410040 — A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis · active not recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02336451 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 21 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02336451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing